Cardiovascular Complications in Cancer Therapy 1st edition by Antonio Russo, Giuseppina Novo, Patrizio Lancellotti, Antonio Giordano, Fausto Pinto ISBN‎ 3030066533 978-3030066536
Original price was: $50.00.$35.00Current price is: $35.00.
Authors:Antonio Russo; Giuseppina Novo; Patrizio Lancellotti; Antonio Giordano; Fausto J. Pinto , Tags:(Current Clinical Pathology) , Author sort:Russo, Antonio & Novo, Giuseppina & Lancellotti, Patrizio & Giordano, Antonio & Pinto, Fausto J. , Ids:Goodreads , Languages:Languages:eng , Published:Published:Oct 2018 , Publisher:Humana , Comments:Comments:This proposed text is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about vascular damage  potentially induced by antineoplastic drugs. Thanks to more and more effective antineoplastic treatments the survival of cancer patients is enormously increasing, but at the same time it is increasing the burden of related cardiovascular complications that affect morbidity and mortality. On this basis a new branch of cardiology has been developed, that is Cardio-Oncology. The aim is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular damage. An increasing attention has been given to cardiac damage, while, until today, vascular complications have been poorly evaluated. The aim of this book is to focus on vascular complications related to cancer treatment, to guide the clinician at facing, during his every day practice, cardiovascular toxicity in cancer and hematologic patients. The proposed sections of the book have been structured to review the molecular mechanisms underlying vascular damage induced by new and old treatments, to describe the various manifestations of vascular disease that may range from artery to venous disease (including coronary artery disease, peripheral arterial disease, venous thromboembolism and pulmonary hypertension), and to provide advice to monitor patients undergoing onco-hematologic treatments in order to prevent and eventually manage vascular damage.This book will address resident and fellow physicians, medical oncologists, cardiologists, general practitioners and all those who take care of these patients.All invited authors will be recognized experts in their field, and leading international researchers on these topics. The editor has worked with these expert colleagues on a variety of other projects. The authors will provide their manuscript according to current literature and clinical research studies. The book does not seek to duplicate or replace other current resources. Rather, it will create a comprehensive yet concise resource on this emerging topic that is not adequately covered by any current literature.
Cardiovascular Complications in Cancer Therapy 1st edition by Antonio Russo, Giuseppina Novo, Patrizio Lancellotti, Antonio Giordano, Fausto Pinto – Ebook PDF Instant Download/Delivery. 3030066533 978-3030066536
Full download Cardiovascular Complications in Cancer Therapy 1st edition after payment
Product details:
ISBN 10: 3030066533
ISBN 13: 978-3030066536
Author: Antonio Russo, Giuseppina Novo, Patrizio Lancellotti, Antonio Giordano, Fausto Pinto
This proposed text is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about vascular damage potentially induced by antineoplastic drugs. Thanks to more and more effective antineoplastic treatments the survival of cancer patients is enormously increasing, but at the same time it is increasing the burden of related cardiovascular complications that affect morbidity and mortality. On this basis a new branch of cardiology has been developed, that is Cardio-Oncology. The aim is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular damage. An increasing attention has been given to cardiac damage, while, until today, vascular complications have been poorly evaluated. The aim of this book is to focus on vascular complications related to cancer treatment, to guide the clinician at facing,during his every day practice, cardiovascular toxicity in cancer and hematologic patients. The proposed sections of the book have been structured to review the molecular mechanisms underlying vascular damage induced by new and old treatments, to describe the various manifestations of vascular disease that may range from artery to venous disease (including coronary artery disease, peripheral arterial disease, venous thromboembolism and pulmonary hypertension), and to provide advice to monitor patients undergoing onco-hematologic treatments in order to prevent and eventually manage vascular damage.This book will address resident and fellow physicians, medical oncologists, cardiologists, general practitioners and all those who take care of these patients.All invited authors will be recognized experts in their field, and leading international researchers on these topics. The editor has worked with these expert colleagues on a variety of other projects.The authors will provide their manuscript according to current literature and clinical research studies. The book does not seek to duplicate or replace other current resources. Rather, it will create a comprehensive yet concise resource on this emerging topic that is not adequately covered by any current literature.
Cardiovascular Complications in Cancer Therapy 1st Table of contents:
Part I: Introduction to Cardiovascular Complications in Cancer Therapy
- Overview of Cardiovascular Disease and Cancer
- Prevalence of Cardiovascular Disease in Cancer Patients
- Mechanisms Linking Cancer and Cardiovascular Diseases
- Importance of Multidisciplinary Care in Cancer Treatment
- Cancer Therapy: Current Trends and Advances
- Overview of Cancer Treatment Modalities (Chemotherapy, Radiation, Targeted Therapy, Immunotherapy)
- Emerging Cancer Treatments and Their Cardiovascular Risks
- Risk Stratification in Cancer Patients Undergoing Therapy
Part II: Mechanisms of Cardiovascular Toxicity in Cancer Therapy
- Chemotherapy and Cardiovascular Toxicity
- Cardiovascular Risks Associated with Traditional Chemotherapies (e.g., Anthracyclines, Cyclophosphamide)
- Mechanisms of Chemotherapy-Induced Cardiomyopathy
- Clinical Manifestations and Management of Chemotherapy-Induced Cardiotoxicity
- Radiation Therapy and Cardiac Damage
- Pathophysiology of Radiation-Induced Heart Disease
- Long-Term Cardiovascular Effects of Chest Radiation (e.g., Breast, Hodgkin’s Lymphoma)
- Risk Factors and Prevention of Radiation-Induced Cardiovascular Complications
- Targeted Therapy and Cardiovascular Risk
- Mechanisms of Cardiovascular Toxicity in Targeted Therapies (e.g., HER2 Inhibitors, Tyrosine Kinase Inhibitors)
- Case Studies: Cardiovascular Side Effects of Targeted Cancer Drugs
- Strategies for Mitigating Cardiovascular Risk in Targeted Therapy
- Immunotherapy and Cardiovascular Complications
- Cardiovascular Effects of Immune Checkpoint Inhibitors (e.g., PD-1/PD-L1, CTLA-4 Inhibitors)
- Inflammation and Autoimmunity in Cancer Immunotherapy-Related Cardiovascular Disease
- Clinical Management of Cardiovascular Events in Immunotherapy
Part III: Specific Cardiovascular Diseases Induced by Cancer Therapy
- Chemotherapy-Induced Heart Failure
- Pathophysiology of Heart Failure Following Cancer Treatment
- Diagnosis and Management of Chemotherapy-Induced Cardiomyopathy
- Clinical Guidelines for Preventing and Managing Heart Failure in Cancer Patients
- Coronary Artery Disease and Angina in Cancer Patients
- Risk Factors for Coronary Artery Disease During and After Cancer Treatment
- Diagnostic Approaches for Identifying CAD in Cancer Patients
- Management of Angina and Other Coronary Syndromes in Cancer Therapy
- Arrhythmias and Cardiotoxicity
- Mechanisms of Arrhythmia Induction by Cancer Treatments
- Common Arrhythmias Observed in Cancer Survivors
- Risk Assessment and Management of Arrhythmic Events During Cancer Therapy
- Hypertension and Vascular Damage
- Chemotherapy, Radiation, and Targeted Therapy-Induced Hypertension
- Mechanisms and Management of Cancer Treatment-Induced Hypertension
- Prevention and Monitoring of Vascular Damage in Cancer Patients
Part IV: Diagnostic Approaches and Monitoring
- Cardiovascular Screening in Cancer Patients
- Screening Guidelines for Cardiovascular Risk in Cancer Therapy
- Role of Imaging Modalities (Echocardiography, MRI, CT) in Assessing Cardiotoxicity
- Biomarkers for Early Detection of Cardiovascular Toxicity
- Monitoring and Surveillance of Cardiovascular Health in Cancer Survivors
- Long-Term Follow-up for Cardiovascular Complications in Cancer Survivors
- Advanced Techniques in Monitoring Heart Function (e.g., Strain Imaging, Myocardial Perfusion Imaging)
- Multidisciplinary Approach to Ongoing Cardiovascular Surveillance
Part V: Management of Cardiovascular Complications in Cancer Therapy
- Cardioprotective Strategies in Cancer Treatment
- Use of Cardioprotective Drugs (e.g., ACE Inhibitors, Beta-Blockers, Statins)
- Novel Approaches to Preventing Cardiotoxicity (e.g., Dexrazoxane, Antioxidants)
- Role of Personalized Medicine in Cardioprotective Strategies
- Management of Heart Failure in Cancer Patients
- Pharmacological Treatment of Cancer Therapy-Induced Heart Failure
- Use of Device Therapy (e.g., ICDs, CRT) in Cancer Patients
- Advanced Heart Failure Management in Cancer Survivors
- Management of Hypertension and Cardiovascular Risk
- Pharmacological Management of Hypertension in Cancer Patients
- Lifestyle Modifications for Reducing Cardiovascular Risk During Cancer Therapy
- Role of Antihypertensive Therapy in Cancer Treatment
- Management of Arrhythmias in Cancer Patients
- Pharmacological Treatment of Arrhythmias in Cancer Survivors
- Device Therapy for Cancer Patients at Risk of Arrhythmias
- Risk Stratification and Prevention of Arrhythmias in Cancer Therapy
Part VI: Special Populations and Considerations
- Pediatric Cancer Survivors and Cardiovascular Health
- Long-Term Cardiovascular Risks in Pediatric Cancer Survivors
- Prevention and Monitoring Strategies in Pediatric Oncology
- Case Study: Pediatric Cardiotoxicity Following Chemotherapy and Radiation
- Elderly Cancer Patients and Cardiovascular Risk
- Cardiovascular Complications in Elderly Cancer Patients
- Tailoring Cancer Therapy to Minimize Cardiovascular Risk in Older Adults
- Multidisciplinary Care for Elderly Cancer Survivors with Cardiovascular Disease
- Women and Cardiovascular Complications in Cancer Therapy
- Gender Differences in Cardiovascular Toxicity of Cancer Treatments
- Impact of Cancer Therapy on Cardiovascular Risk in Women (e.g., Breast Cancer)
- Special Considerations for Women’s Cardiovascular Health During Cancer Treatment
Part VII: Future Directions and Research
- Emerging Therapies and Cardiovascular Risk
- New Cancer Therapies and Their Potential Cardiovascular Risks
- Advances in Precision Medicine for Minimizing Cardiovascular Toxicity
- Ongoing Research in Cardio-Oncology
- The Role of Artificial Intelligence and Big Data in Cardio-Oncology
- Machine Learning and AI in Predicting Cardiovascular Complications
- The Use of Big Data for Risk Stratification in Cancer Survivors
- Future Directions in AI for Monitoring and Managing Cardiotoxicity
People also search for Cardiovascular Complications in Cancer Therapy 1st:
cardiovascular complications of cancer therapy
cardiovascular disease in cancer survivors
cardiovascular cancer treatment
cancer therapy-related cardiac dysfunction
can chemotherapy cause heart issues
You may also like…
